CWA Asset Management Group LLC Cuts Position in GSK plc (NYSE:GSK)

CWA Asset Management Group LLC trimmed its stake in GSK plc (NYSE:GSK - Free Report) by 65.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,210 shares of the pharmaceutical company's stock after selling 30,397 shares during the period. CWA Asset Management Group LLC's holdings in GSK were worth $548,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in GSK. Strategic Financial Concepts LLC purchased a new position in GSK in the second quarter worth $129,000. Caprock Group LLC increased its position in GSK by 115.6% during the 2nd quarter. Caprock Group LLC now owns 26,000 shares of the pharmaceutical company's stock valued at $1,011,000 after buying an additional 13,943 shares in the last quarter. PFG Investments LLC raised its stake in GSK by 3.5% in the second quarter. PFG Investments LLC now owns 15,273 shares of the pharmaceutical company's stock valued at $588,000 after buying an additional 515 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in GSK in the second quarter worth about $37,000. Finally, Choreo LLC grew its stake in shares of GSK by 759.4% during the second quarter. Choreo LLC now owns 52,157 shares of the pharmaceutical company's stock worth $2,002,000 after acquiring an additional 46,088 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on GSK shares. Deutsche Bank Aktiengesellschaft cut shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Guggenheim downgraded shares of GSK from a "buy" rating to a "neutral" rating in a research note on Thursday, October 31st. StockNews.com lowered GSK from a "strong-buy" rating to a "buy" rating in a research note on Sunday. Finally, Jefferies Financial Group lowered GSK from a "buy" rating to a "hold" rating and cut their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven equities research analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $43.25.

GSK Stock Performance

Shares of GSK stock traded down $0.37 on Thursday, hitting $33.72. The company had a trading volume of 2,709,096 shares, compared to its average volume of 2,795,279. GSK plc has a twelve month low of $32.83 and a twelve month high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The firm has a market cap of $69.89 billion, a P/E ratio of 21.90, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. The company has a 50-day moving average price of $34.46 and a 200-day moving average price of $38.24.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be paid a $0.3928 dividend. This is a boost from GSK's previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.66%. The ex-dividend date is Friday, November 15th. GSK's payout ratio is currently 98.70%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.